Bio­gen scut­tles a Tysabri pro­gram af­ter the drug fails stroke test, thin­ning the pipeline

Bio­gen’s hopes of ex­pand­ing its fran­chise for Tysabri (na­tal­izum­ab) by break­ing in­to is­chemic stroke just flopped, leav­ing the big biotech with one less pro­gram in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER